Analyst Report: COO

1. EXECUTIVE SUMMARY

Shares of The Cooper Companies, Inc. (NASDAQ: COO) plummeted 6.22% to close at $63.48 on September 09, 2026, on heavy trading volume exceeding 8.38 million shares (more than 3.5 times the daily average), before extending losses further in after-hours trading. The sharp sell-off was triggered by the company's fiscal Q3 2026 earnings report, in which COO missed quarterly revenue expectations ($1.066B reported vs. $1.10B consensus) and significantly lowered both Q4 and full-year FY2026 guidance due to proactive U.S. channel inventory reductions (destocking) at CooperVision. Compounding investor disappointment, management formally concluded its months-long strategic review of the CooperSurgical division without pursuing a sale or spinoff, citing low offers caused by fertility litigation settlements and new competitive threats in the non-hormonal IUD market. While record quarterly free cash flow ($273M) and an expanded $3.0 billion share repurchase program offer fundamental downside protection, near-term channel headwinds and reduced multi-quarter visibility leave the stock structurally impaired in the short term.

2. THE CATALYST (CRITICAL)

Primary Trigger: Q3 Revenue Miss, Guidance Cut, and Aborted Strategic Sale

On the afternoon of September 09, 2026, after market close (with defensive positioning driving the -6.22% loss during regular trading hours), The Cooper Companies announced financial results for its fiscal third quarter ended July 31, 2026:

1. Top-Line Miss & Channel Destocking:
   • Q3 Revenue: $1.066 Billion (+1% YoY reported / +1% organic) vs. Wall Street consensus of $1.10 Billion (a ~$34M miss).
   • Division Breakdown: CooperVision revenue was flat YoY at $717.0 million, impacted directly by management’s decision to aggressively clear U.S. distributor channel inventory. CooperSurgical revenue rose 2% reported (3% organic) to $349.2 million.
2. Earnings Performance:
   • Non-GAAP Diluted EPS: $1.15 (+4% YoY), topping consensus estimates of $1.12 by $0.03.
   • GAAP Diluted EPS: $2.24 (vs. $0.49 in Q3 FY25), heavily inflated by a $307.2 million discrete non-cash tax benefit following the favorable resolution of a U.K. HMRC tax audit regarding FY2021 IP transfers.
3. Severe Guidance Downgrade:
   • Q4 FY2026 EPS Guidance: $1.05 – $1.09 vs. Wall Street consensus of $1.20.
   • Q4 FY2026 Revenue Guidance: $1.057B – $1.080B vs. consensus of ~$1.11B.
   • Full-Year FY2026 EPS Guidance: Lowered to $4.51 – $4.55 (down from $4.58 – $4.66 prior), below consensus of $4.63.
   • Full-Year FY2026 Revenue Guidance: Lowered to $4.229B – $4.252B (down from $4.285B – $4.321B prior), well below consensus of $4.31B.
4. Termination of CooperSurgical Strategic Review:
   • Management officially ended its strategic review of CooperSurgical, opting to retain the asset rather than execute a divestiture or tax-free spinoff.
   • Reasoning: Offers received reflected a "valuation disconnect" due to recent market developments, including a new competitive entrant in the non-hormonal intra-uterine device (IUD) market and lingering liabilities from recent fertility litigation settlements.

Timeline & Documentation

• September 09, 2026 (4:15 PM EDT): Q3 FY2026 financial results press release and SEC Form 8-K filed.
• September 09, 2026 (5:00 PM EDT): Q3 Earnings Call led by CEO Albert White and CFO Brian Andrews detailing U.S. channel destocking schedules and strategic review cancellation.

3. COMPANY PROFILE

Business Description

The Cooper Companies, Inc. (NASDAQ: COO) is a global medical device corporation headquartered in San Ramon, California. Operating in over 130 countries, the company functions through two core business segments:

1. CooperVision: A market leader in contact lenses, offering spherical, toric, multifocal, and specialty lenses (brands include MyDay, Biofinity, and MiSight myopia management).
2. CooperSurgical: Focused on fertility solutions (assisted reproductive technology/IVF products) and women's healthcare (intrauterine devices, surgical instruments, and diagnostics).

Fundamental Metrics

4. DEEP DIVE ANALYSIS

                       +-----------------------------------+
                       |    Q3 FY2026 CATALYST METRICS    |
                       +-----------------------------------+
                                         |
         +-------------------------------+-------------------------------+
         |                                                               |
         v                                                               v
  [ TOP-LINE / GUIDANCE ]                                         [ CAPITAL / CASH ]
  • Q3 Rev: $1.066B (vs $1.10B Est)                              • Free Cash Flow: $273M (+66% YoY)
  • Q4 EPS Guidance: $1.05-$1.09 (vs $1.20 Est)                  • Buyback Auth: Boosted +$1B to $3.0B
  • FY26 Rev Cut: $4.23B-$4.25B (vs $4.31B Est)                   • Discrete Tax Benefit: $307.2M

Fundamentals vs. Market Overreaction

While a -6.22% drop in regular trading (and subsequent post-market pressure) reflects significant institutional frustration, the operational breakdown is partially transient but structurally disappointing:

1. The Inventory Destocking Realignment: Management explicitly stated that underlying consumer demand for contact lenses in the U.S. remains in the mid-single digits. The top-line miss at CooperVision was self-inflicted—a proactive decision to drain excess inventory from U.S. distributor channels. While this penalizes reported revenue through Q4, end-patient consumption has not collapsed.
2. The Strategic Review Failure: The major long-term disappointment stems from CooperSurgical. Investors had priced in a sum-of-the-parts re-rating via a sale or spinoff of CooperSurgical to create a pure-play vision enterprise. The inability to monetize CooperSurgical due to new competitive non-hormonal IUD products and fertility settlement liabilities effectively eliminates a key near-term valuation driver.
3. Cash Flow and Balance Sheet Strength: Free cash flow surge to $273 million (+66% YoY) and the $1 billion expansion of the stock repurchase program (bringing total authorization to $3.0 billion) demonstrate that the underlying cash-generation engine is intact.

Bull Case vs. Bear Case

• Bull Case:

  • End-Market Resiliency: Daily disposable and specialty lens transition (MyDay/MiSight) continues to generate high-margin organic growth once channel inventories balance out in early FY2027.
  • Accretive Capital Allocation: Utilizing the $3.0 billion buyback at multi-year valuation lows ($63.48 vs. 52-week high of $89.83) will aggressively reduce share count and boost EPS recovery.
  • Strong Balance Sheet: Low leverage (Debt-to-Equity of 0.23) and record free cash flow generation mitigate macro risks.

• Bear Case:

  • Loss of Management Credibility: Unscheduled destocking and lower full-year guidance reduce confidence in management's forecasting capabilities.
  • CooperSurgical Structural Drag: Retention of CooperSurgical keeps the firm exposed to rising competition in non-hormonal contraceptive devices and legal tail-risk from fertility litigation.
  • Peer Outperformance: Competitors like Alcon (ALC) continue to gain market share in premium daily lens categories without inventory friction.

5. TECHNICAL SNAPSHOT

Price Level ($)
 90.00 |---------------------------------------- 52-Week High ($89.83)
       |
 72.59 |---------------------------------------- 50-Day SMA
 70.17 |---------------------------------------- 200-Day SMA
       |
 63.48 |======================================== CURRENT PRICE (Sept 09 Close)
 58.89 |---------------------------------------- 52-Week Support / Low

• Key Support Levels: $58.89 (52-week low set earlier in 2026), followed by major long-term structural support at $53.00 – $54.00.
• Key Resistance Levels: $70.17 (200-day SMA), $72.59 (50-day SMA), and $80.00 (psychological target).
• Volume Analysis: Trading volume spiked to 8,383,881 shares on Sept 09, 2026 vs. normal daily volume of ~2.35 million, confirming severe institutional distribution and liquidation.
• Technical Breakdown: The stock breached both its 50-day and 200-day moving averages on accelerating volume. The RSI is entering deep oversold territory (<30), signaling high likelihood of a temporary technical bounce once panic selling cools.

6. RISK FACTORS

1. Extended Destocking: Risk that channel inventory correction in U.S. CooperVision accounts spills beyond Q4 FY2026 into early FY2027.
2. Competitive Pressure in Women's Health: Emerging non-hormonal IUD options threaten CooperSurgical’s market share and margin profile.
3. Litigation Overhang: Unresolved or future liabilities stemming from fertility clinic media/equipment settlements at CooperSurgical.
4. Foreign Exchange Volatility: Currency headwinds continue to pressure top-line international growth.

7. ACTIONABLE OUTLOOK

Conclusion

The sell-off in COO on September 09, 2026, reflects a painful double disappointment: lower-than-anticipated Q4/FY26 guidance tied to inventory destocking and the cancellation of a valuation-unlocking sale of CooperSurgical. However, with the stock trading near 52-week lows, carrying a forward P/E compressed well below historical averages, and backed by a $3.0B buyback and record free cash flows, patient institutional investors should monitor the $55–$58 support zone for long-term entry opportunities.